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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Enbrel 
(etanercept) is safe and effective in treating patients with sciatic nerve pain resulting from lumbar disc 
herniation or spinal stenosis. 
 
STUDY DESIGN: Review of three English language primary randomized controlled trials from 2012-
2013. 
 
DATA SOURCES: One triple-blind, placebo-controlled randomized clinical trial, one double-blind, 
placebo-controlled randomized clinical trial, and one prospective randomized clinical trial were found 
using PubMed. These studies compared treatment with etanercept to treatment with saline and steroids 
(dexamethasone or methylprednisolone).  
 
OUTCOMES MEASURED: Clinical outcomes of leg and back pain were measured using numeric pain 
rating scales, global perceived effect (GPE) surveys, and the oswestry disability index (ODI). 
 
RESULTS: One triple-blind and one double-blind placebo controlled trial were reviewed, in addition to 
one prospective randomized trial. Cohen et al did not find any statistically significant differences in pain 
relief between the etanercept and saline groups, and subjects in the etanercept group did not experience 
any improvement in disability. Freeman et al found clinically and statistically significant improvements in 
leg and back pain as well as improvements in disability in the etanercept group when compared to 
placebo. Ohtori et al found that etanercept provided better pain relief and improvement in disability than 
dexamethasone. However, this difference was not statistically significant. 
 
CONCLUSIONS: Based on the studies reviewed in this paper, the evidence is conflicting in determining 
whether or not etanercept is safe and effective in treating radiculopathy and sciatica resulting from lumbar 
herniation and spinal stenosis. 
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INTRODUCTION: Lower back pain (LBP) affects millions of men and women despite 
demographic and socioeconomic differences. Lumbar radicular pain is the leading cause of 
disability worldwide1. Sciatic pain (sciatica) is a type of radicular nerve pain in which pain 
travels down the path of the sciatic nerve2. For many years, clinicians have searched for safer and 
more effective solutions to alleviate radiculopathy, as current therapies often fail to provide 
continuous and efficacious pain relief. Epidural injections seem to benefit only a subset of 
patients, and the effectiveness of invasive surgical therapies fails to supersede that of 
conservative treatments3. Recently, attention has shifted towards a new mechanism of LBP. 
Tumor necrosis factor alpha (TNF-α) and other mediators of inflammation are implicated with 
radicular pain and have become newly promising targets of pain management3. High 
concentrations of TNF-α have been noted in patients with disc degeneration, and preclinical 
trials have confirmed this suspicion by experimentally applying TNF to nerve roots of 
participants, finding that this produces sensations of pain consistent with that of a herniated disc3. 
Successful management of LBP is critical for improvement in overall quality of life for the 80% 
of Americans affected by low back pain at some point1. Annual care costs for these patients are 
estimated at $50 billion, making back pain the second most common complaint at physician 
visits1. In addition to the economic strain created by the cost of treatment and management, LBP 
heavily affects the work force, as it is one of the leading causes for work place absenteeism1. 
 Most cases of LBP in those under 50 years of age are attributable to herniated discs, 
resulting in compression of the affected nerve root(s) and initiation of an inflammatory cascade 
that includes the release of cytokines and TNF-α4. The result is radicular pain: a distinct form of 
pain that travels down the leg, following the trajectory of the affected nerve root. Symptoms may 
include sharp, radiating pain down the back and/or leg that may be accompanied by numbness, 
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weakness, and diminished deep tendon reflexes5. Conventional treatments for radicular back pain 
are implemented in a step-wise fashion, beginning with non-pharmacological methods like 
chiropractic/osteopathic manipulation and physical therapy6. Medications such as non-steroidal 
anti-inflammatories (NSAIDs) may be used independently or as adjunctive therapy to the 
aforementioned methods6. Next, a trial of opioid analgesics, muscle relaxers, or epidural steroid 
injections may be indicated6. Surgical methods such as discectomies, disc replacements, and 
decompressive spinal fusion are reserved for recalcitrant cases of lumbar radiculopathy6. Current 
treatments may be effective in treating acute pain, but have mixed efficacy with regard to long-
term pain management4. Enbrel (etanercept) may be used to inhibit the inflammatory mediator 
TNF- α, relieving radiculopathy and sciatica more effectively than conventional methods.  
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Enbrel 
(etanercept) is safe and effective in treating patients with sciatic nerve pain resulting from lumbar 
disc herniation or spinal stenosis. 
METHODS:  Two randomized controlled trials and one prospective randomized trial were 
selected for this review. These studies consisted of patients ages 18-80 with an established 
diagnosis of lumbosacral radiculopathy (continuous low back or leg pain for at least 4-6 weeks). 
All three studies encompassed wide demographic parameters, though two of the studies were 
predominantly male and one study was predominantly Caucasian. In all three studies, treatment 
and placebo groups were comparable with regard to age, race, and mean duration/severity of 
pain. Inclusion and exclusion criteria of all three studies were similar. These criteria, as well as 
study-specific demographics, can be found in Table 1. Each RCT studied the use of epidural or 
transforaminal etanercept. Patients received either bupivacaine or lidocaine injections prior to 
treatment. Comparison groups included epidural steroids (methylprednisone or dexamethasone) 
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and saline. Outcomes measured were reduction in radicular/sciatic nerve pain and safety (# of 
adverse events). Studies were required to be peer-reviewed, published, randomized controlled 
trials to meet the inclusion criteria for this review. Articles published prior to the year 2000 were 
excluded. All studies were retrieved through the PubMed database in 2015. Key words used in 
the data search were “sciatica” and “etanercept.” All articles were published in English between 
the years of 2012-2013 and research was completed by the author of this review. Articles were 
selected based on relevance and the presence of patient oriented outcomes. Statistics reported in 
this review include relative benefit increase, absolute benefit increase, number needed to treat, 
relative risk increase, absolute risk increase, number needed to harm, and p-values. 
Study Type #Pts Age Inclusion Criteria Exclusion Criteria W/D Interventions 
Cohen, 2012 
(4) 
RCT  84 18-70 Age 18-70; lumbosacral 
radiculopathy >4wks, <6mo; leg 
pain that ≥ as severe as back 
pain; failed conservative 
therapy; evidence of pathologic 
disc condition on MRI that 
matches sx 
Persons w/ coagulopathy or 
systemic infection; unstable medical 
or psychiatric condition; previous 
spinal surgery or previous epidural 
steroid injection; allergy to contrast 
dye 
0 dropouts, 
46 “exit per 
study 
protocol” 
Epidural injection 
of 4mg etanercept 
in 2mL of sterile 
water  
Freeman, 
2013 (7) 
RCT 49 18-70 18-70y/o, good medical/ 
psychological health, capable of 
completing procedures; not 
breastfeeding, pregnant, or 
becoming pregnant; avg leg pain 
of 5/10 for at least 3-7d before 
randomization visit; dx of 
radicular pain b/w 6-26wks 
duration; pain in dermatomal 
distribution c/w involved nerve 
root; dx confirmed by CT/MRI 
w/in 6mo of screening visit; + 
straight leg, femoral stretch test; 
herniation affecting L3/4/5 or 
S1; -TB test; willingness to 
stabilize or decrease analgesic 
use 
Hx of sciatica in currently affected 
leg; allergy to etanercept, 
oxycodone, hydrochloride, or  
contrast; BMI >35; major 
psychiatric d/o not controlled; 
abnormalities in AST/ALT or 
creatinine clearance <70mL/min; 
pain unrelated to disc herniation; 
polyradiculopathy; investigational 
drug received w/in 30d of screening; 
prior disc surgery; epidural steroids 
w/in 6mo of screening; worker’s 
comp, disability, or litigation 
involvement; infection, malignancy, 
or demyelinating dz; use of anti-
TNF w/in 1yr; severe stenosis; 
coagulopathy; psoriatic arthritis, AS, 
or RA; cyclophosphamide therapy;  
Wegener granulomatosis  
4 d/c due to 
adverse 
events, 1 
withdraw 
of consent, 
1 protocol 
violation 
Transforaminal 
epidural injection 
of etanercept 
(0.5mg, 2.5mg, or 
12.5mg) 
Ohtori, 2012 
(2) 
PRT 
 
 
80 49-80 LBP/leg pain for ≥1mo; dx of 
spinal stenosis by X-Ray, MRI, 
and PE, confirmation by spinal 
infiltration 
Previous spinal surgery; spinal 
tumor/infection/trauma; cauda 
equina syndrome or 
polyradiculopathies 
0 Epidural injection 
of 10mg etanercept 
w/ 2.0mL of 
lidocaine 
Table 1: Demographics and Characteristics of studies included 
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OUTCOMES MEASURED: Each RCT studied in this review used investigator and patient self-
report measures to determine the efficacy and safety of etanercept. With regard to investigator 
measures, Cohen et al documented the number of subjects that required further intervention after 
treatment with etanercept vs. comparison4. Freeman et al documented the number adverse events 
with etanercept treatment vs. comparison (including worsening sciatica, headache, nausea, 
diarrhea, and constipation)7. All three studies used the oswestry disability index (ODI) and either 
a visual analog scale (VAS) or a numeric rating scale (NRS) as patient self-report measures for 
pain. Two studies used global perceived effect surveys (GPEs). Cohen et al obtained data 
through a physician or research nurse blinded to the treatment groups4. Leg pain, the primary 
outcome measured in this study, was determined by a NRS at 1 month post-injection (0= no 
pain, 10= worst pain) 4. Secondary measures included a NRS for back pain, ODI (10 question 
survey assessing disability) and GPE (response to the following question: my pain has 
improved/worsened/stayed the same since my last visit) 4. Freeman et al collected numerical 
leg/back pain data through daily subject study diaries that documented pain levels, medication 
use, and adverse events7. This study also employed ODI and GPE measures at 4 and 12 weeks 
post-injection7. Ohtori et al evaluated leg and back pain using a VAS (0= no pain, 10= worst 
pain) before the injection as well as 30 minutes, 3 days, 1 week, 2 weeks, and 4 weeks after 
injection2. In addition, ODI scores were measured prior to treatment and 4 weeks post-injection2. 
RESULTS: The 2012 Cohen et al study comparing epidural etanercept to methylprednisolone 
and saline was a triple-blind, placebo controlled RCT4. Eighty-four men and women ages 18-70 
were enrolled in the study and 46 subjects exited “per protocol” (0 dropouts)4. This study was 
conducted at 3 United States military centers using outpatient pain clinic patients who were 
either veterans or military dependents4. Detailed inclusion and exclusion criteria are included in 
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Table 1. These criteria included a diagnosis of lumbosacral radiculopathy >4 weeks but < 6 
months in duration, leg pain more than or as severe as back pain, and failed conservative 
therapy4. Excluded patients were those with coagulopathy or infection, due to the 
immunosuppressive properties of etanercept, and those with a contrast dye allergy, as contrast 
was used for identification of epidural uptake4. A research nurse stratified the participants into 
three groups using randomized, computer generated tables4. All groups received contrast dye, 
followed by 0.5mL of 0.5% bupivacaine and the assigned treatment: 60mg of 
methylprednisolone acetate in 0.5mL of saline (Group 1), 4mg of Enbrel (etanercept) in 2mL of 
normal saline (Group 2), or 2mL of normal saline (Group 3)4. This review focuses on comparing 
the effectiveness of etanercept (n = 26) and saline (n = 30). Each group received 2 injections, one 
at the beginning of the study, and another 2 weeks later. A NRS was used at baseline and 1 
month after the second injection to assess leg and back pain. Compliance is considered to be 
88% overall, as it was determined by the amount of patients who received both injections. Some 
patients refused a second injection due to lack symptom relief (n=5) or pain cessation less than 
expected (n=5) 4. 
The mean baseline NRS scores for leg pain and back pain in the etanercept and saline 
groups can be seen in Table 2. After 1 month, mean NRS score for leg pain in the etancercept 
group was 3.56 vs. 3.78 in the saline group (omnibus p-value of 0.24) and mean NRS score for 
back pain in the etanercept group was 4.41 vs. 4.01 in the saline group (omnibus p-value of 
0.40)4. Differences in pain between the two groups were -0.25 (p = 0.75) for leg pain and 0.40 (p 
= 0.56) for back pain4. With regard to the GPE, 57% of saline group subjects and 58% of 
etanercept group subjects were satisfied with the treatment4. There was no improvement in ODI 
scores at 1 month for the etanercept group4. Overall, 42.3% of subjects in the etanercept group, 
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vs. 50% of subjects in the saline group, reported successful treatment outcomes at 1 month. 
Therefore, the resultant NNT is -12 (Table 3), indicating that, for every 12 patients treated with 
etanercept instead of saline, one fewer patient will experience a reduction in back pain compared 
to those treated with saline. 
 With regard to harm, 10.8% of patients in the saline group and 15.4% of patients in the 
etanercept group experienced worsening pain, resulting in a NNH of 22. Therefore, for every 22 
patients being treated with etanercept instead of saline, one additional patient will experience 
worsening back pain (Table 4).  
Table 2: Baseline and 1mo scores for leg and back pain and mean change in leg and back pain from Cohen et al data 
Table 2 illustrates a between group difference (saline and etanercept) of -0.25 (p = 0.75) for leg pain and 0.40 (p = 
0.56) for back pain 1 month after administration of the second injection. All CIs are 95%. 
Table 3: Calculations for treatment from Cohen et al data 
Table 3 illustrates a NNT of -12, indicating that for every 12 patients treated with etanercept instead of saline, one 
fewer patient will experience a reduction in back pain. 
Table 4: Calculations for harm from Cohen et al data 
Table 4 illustrates a NNH of 22, indicating that for every 22 patients treated with etanercept instead of saline, one 
additional patient will experience worsening back pain. 
The 2013 Freeman et al study comparing etanercept to placebo was a double-blind, 
placebo controlled RCT7. Fifty-one men and women between the ages of 18-70 years old were 
enrolled and randomized, with 49 of those receiving the full treatment regimen, 43 of those 
completing the study, and 37 of those meeting the criteria to be included in the PP population7. 
Therefore, 75.5% of all subjects who received full treatment were compliant (per protocol). Per 
protocol (PP) patients were those who received 2 doses of medication with confirmed needle 
 Baseline NRS 
(leg pain) 
Baseline NRS 
(back pain) 
1 month NRS 
(leg pain) 
1 month NRS 
(back pain) 
Mean change 
in leg pain 
Mean change in 
back pain 
Etanercept 
(n=26) 
6.62 (1.66) 6.08 (2.51) 3.56  (2.35 to 
4.72) 
4.41 (3.37 to 
5.44) 
-2.98 (-4.41 to -
1.55) 
-1.56 (-2.83 to -
0.28) 
Saline 
(n=30) 
6.31 (2.02) 4.75 (2.49) 3.78 (2.72 to 
4.85) 
4.01 (3.08 to 
4.93) 
-2.48 (-3.59 to -
1.37) 
-1.07 (-1.96 to -
0.17) 
CER EER Relative benefit increase (RBI) Absolute benefit increase (ABI) Number needed to treat (NNT) 
50% 42.3% .154% -7.7% -12 
CER EER Relative risk increase (RRI) Absolute risk increase (ARI) Number needed to harm (NNH) 
10.8% 15.4% 42.6% 4.6% 22 
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placement and contrast flow during both injections7. These patients were also required to 
complete at least one pain assessment at 4 weeks post-injection7. This review evaluates the 
findings within the PP population, which included patients from 5 medical hospitals and 1 spinal 
clinic in Australia7. Detailed inclusion and exclusion criteria can be seen in Table 1. The criteria 
included patients with a diagnosis of lumbosacral back pain lasting 6-26 weeks, confirmed by 
radiology, and accompanied by an average pain score of at least 5 out of 107. Patients with 
systemic or chronic infections, demyelinating disease, and known contrast dye allergies were 
excluded7. Subjects were randomized by a computer generated randomization schedule, and an 
investigational pharmacist prepared the treatments7. Clinicians preforming injections, reading 
films, and stratifying data were blinded7. Subjects received either etanercept (0.5mg, 2.5mg, or 
12.5mg) or placebo7. Freeman et al did not specify the type of placebo used. This review focuses 
on comparing 0.5mg of etanercept to placebo. All patients received 2mL of 1% lidocaine intra-
dermally as well as 2.0mL of contrast medium prior to receiving 2 transforaminal injections of 
either etanercept or placebo 2 weeks apart (one injection at 2 weeks, another at 4 weeks) 7. 
Freeman et al used a NRS to evaluate changes in mean daily worst leg pain (WLP) from 
baseline to 4 weeks as the primary outcome measure7. Secondarily, changes in mean daily worst 
back pain (WBP), ODI, and GPE were evaluated7.  Freeman et al found that 50% of the patients 
treated with 0.5mg of etanercept reported 100% reduction in daily WLP scores when evaluated 4 
weeks after the second injection, while 0% of subjects in the placebo group experienced this 
treatment effect 7. This finding was significant both clinically and statistically. This yields an 
ARR of 50%, meaning that patients treated with 0.5mg etanercept had a 50% absolute decrease 
in sciatic leg pain compared to placebo (Table 5). The group treated with 0.5mg etanercept also 
had a statistically significant decrease in WLP between baseline and 26 weeks. Patients treated 
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with etanercept 0.5mg experienced a 5.1 point decrease in WLP vs. a 1.9 point decrease in WLP 
for placebo (p = 0.058) 7.  This clinical and statistical significance remained with WBP scores. 
Two weeks after the first injection, >63% of subjects treated with 0.5mg etanercept, compared to 
10% of patients treated with placebo, reported that they were “much improved” or “very much 
improved” when evaluated by the ODI 7. This yields a NNT of 2, meaning that for every 2 
patients treated with 0.5mg of etanercept compared to placebo, one additional patient will have 
clinically significant relief of leg and/or back pain (Table 6). Three months after the second 
injection, ODI scores improved ≥10 points in the etanercept group, with disability reduced by 
30% or more compared to placebo7. With regard to GPE, 63% of patients being treated with 
0.5mg of etanercept rated their symptoms as “significantly improved,” compared to 10% of 
subjects being treated with placebo7. With regard to safety, both groups experienced similar rates 
of adverse events (59% etanercept, 67% placebo), including continuing or worsening sciatica, 
headache, nausea, diarrhea, and constipation (Table 7) 7. The dosage of etanercept did not appear 
to be related to the incidence of adverse effects. 
Table 5: Calculations for prevention from Freeman et al data 
Table 5 illustrates an ARR of 50%, meaning that patients treated with 0.5mg etanercept had a 50% absolute decrease 
in sciatic leg pain compared to placebo 
Table 6: Calculations for treatment from Freeman et al data  
Table 6 illustrates an NNT of 2, meaning that for every 2 patients treated with 0.5mg of etanercept compared to 
placebo, one additional patient will experience clinically significant relief of leg and back pain. 
Table 7: Calculations for harm from Freeman et al data 
Table 7 illustrates a NNH of -13, meaning that for every 13 patients treated with 0.5mg of etanercept, one fewer 
patient will experience an adverse event such as sciatica, headache, nausea, diarrhea, or constipation. 
CER EER Relative risk reduction (RRR) Absolute risk reduction (ARR) Number needed to treat (NNT) 
0% 50% 50% 50% 2 
CER EER Relative benefit increase (RBI) Absolute benefit increase (ABI) Number needed to treat (NNT) 
10% 63% 5.3% 53% 2 
CER EER Relative risk increase (RRI) Absolute risk increase (ARI) Number needed to harm (NNH) 
67% 59% -.11% -8% -13 
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The 2012 Ohtori et al study comparing epidural injection of etanercept to dexamethasone 
was a prospective randomized trial based in Japan (Chiba University Graduate School of 
Medicine)2. Eighty men and women, ages 49-80, were randomized using the minimization 
allocation method2. Compliance was not discussed, however, all 80 subjects provided ODI 
responses at 4 weeks post-injection without being lost to follow-up2. Detailed inclusion and 
exclusion criteria are in Table 1. Patients considered for inclusion had LBP/leg pain for at least 1 
month with diagnosed lumbar stenosis clinically, by XRay/MRI, and with confirmation VIA 
spinal infiltration2. Patients with previous spinal surgery, trauma, cauda equine syndrome or 
polyradiculopathy were excluded, presumably because these anatomical and neurological 
variants pose a higher risk for complications2. All subjects received a 1.5mL intradermal 
injection of 1% lidocaine, followed by the respective treatment: either 2.0mL of lidocaine and 
10mg of etanercept (n = 40) or 2.0mL of lidocaine and 3.3mg of dexamethasone (n = 40) 2. Pain 
was evaluated using a VAS at baseline, then at 30 minutes, 3 days, 1, 2, and 4 weeks post-
injection2. Patients also reported ODI scores at baseline and 4 weeks post-injection2.  
Ohtori et al found no statistically significant difference between groups in leg/back pain 
VAS scores or ODI scores (p > 0.05) 2. However, both groups had statistically significant relief 
of leg pain up to 4 weeks post-injection (p < 0.026). Average leg pain scores were notably lower 
in the etanercept group than the dexamethasone group at 3 days, 1, 2, and 4 weeks post-injection 
( p < 0.05) 2. VAS scores for LBP in the etanercept group were lower than dexamethasone scores 
at 3 days, 1 week, and 2 weeks post-injection (p < 0.05) 2. Overall, 85% of patients in the 
etanercept group, compared to 73% of patients in the dexamethasone group, selected the answer 
“treatment met my expectations” or “I would undergo the same treatment for the same outcome” 
on the ODI survey at 4 weeks post-injection2. This yields a NNT of 9, meaning that for every 9 
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patients treated with 10mg of etanercept compared to dexamethasone, one additional patient will 
experience clinical improvement of sciatica (Table 8). 
Table 8: Calculations for treatment using ODI scores from Ohtori et al 
Table 8 illustrates a NNT of 9, meaning that for every 9 patients treated with 10mg of etanercept compared to 
dexamethasone, one additional patient will experience clinical improvement of sciatica.  
 
 
 
 
 
DISCUSSION:  This review examines the use of etanercept compared to dexamethasone and 
saline in the management of spinal radiculopathy and sciatica. Cohen et al found no clinical or 
statistical significance in leg or back pain between patients treated with etanercept vs. saline, nor 
did the etanercept subjects report any improvement in disability. In fact, there was a 4.6% higher 
incidence of worsening pain in the etanercept group. Ohtori et al found that both of these 
treatments were safe and effective in providing significant pain relief up to 4 weeks post-
injection, though etanercept provided better pain relief (Table 9, 10) and reduction in disability. 
These results were not statistically significant. Unlike the other two studies reviewed in this 
paper, Freeman et al did find a clinically and statistically significant difference in leg and back 
pain between groups, with half of the etanercept subjects experiencing 100% relief of leg pain 
after 1 month. This group also experienced a higher reduction in disability when compared to 
placebo. These studies failed to compare etanercept with non-invasive methods of treatment like 
CER EER Relative benefit increase (RBI) Absolute benefit increase (ABI) Number needed to treat (NNT) 
73% 85% 0.164% 12% 9 
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physical therapy. This review is limited by the lack of exclusion criteria used in the selection of 
studies. Differences in treatment effectiveness based on sex, race, and age are not addressed. The 
studies in this review were limited by small sample sizes, short follow-ups, reliance on patient 
self-report measures, and the use of injections on a set basis rather than as needed. Enbrel 
(etanercept) is indicated in the treatment of Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, 
Ankylosing Spondylitis, and Juvenille Idiopathic Arthritis8. In 2012, Bonafede et al estimated the 
annual cost of etanercept to be $14,543.009. It is unclear whether insurance will cover the cost of 
treatment for off-label indications like radiculopathy and sciatica. Etanercept is contraindicated 
in patients with sepsis and has US Boxed Warnings for Lymphoma and Tuberculosis10.  
CONCLUSION: Based on the studies reviewed in this paper, the evidence is conflicting in 
determining whether or not etanercept is safe and effective in treating radiculopathy and sciatica 
resulting from lumbar disc herniation and spinal stenosis. Of the 3 studies reviewed in this paper, 
only one was able to prove the efficacy and safety of etanercept with clinical and statistical 
significance. Future studies of epidural etanercept for spinal radiculopathy and sciatica could 
greatly benefit from a longer follow-up period. The clinical trials of etanercept used in this 
review failed to establish long-term efficacy: a major disadvantage of current conventional 
therapies and an ongoing area of investigation in the management of LBP. The NIH does not 
acknowledge any currently ongoing studies of etanercept in the treatment of radiculopathy and 
sciatica, but there are 56 clinical studies in progress which evaluate the use of etanercept in a 
multitude of other conditions. In further studies of etanercept, a comparison of low doses on an 
as needed basis may be most useful, given that the best results in this paper came from the lowest 
dose of epidural etanercept studied. In addition, efforts should be made to compare the efficacy 
of etanercept to other anti-TNF inhibitors, such as infliximab and adalimumab. 
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